8
Participants
Start Date
March 22, 2018
Primary Completion Date
August 30, 2019
Study Completion Date
April 24, 2020
MP0250 DARPin® drug candidate, Osimertinib
Number of Cycles: until progression, unacceptable toxicity or other reasons for withdrawal
Georgetown University, Washington D.C.
Duke Cancer Institute, Durham
Florida Hospital, Orlando
Tennessee Oncology, Nashville
UT Southwestern Medical Center, Dallas
Oncology Consultants, Houston
Scottsdale Healthcare Hospitals, Scottsdale
UCLA Medical Center, Santa Monica
City of Hope - Comprehensive Cancer Center, Duarte
University of California, San Diego
Lead Sponsor
Molecular Partners AG
INDUSTRY